Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the Stocks That Could Mint Millionaires in 2026.

On December 16, UBS analyst Ashwani Verma initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock with a Neutral rating and $95 price target. In an investor note, the analyst cited valuation for the Neutral rating, with the shares up 64% year-to-date. Per the analyst, the stock was already pricing in both the continued growth in hypercortisolism and Corcept’s new launch opportunity in platinum-resistant ovarian cancer.

In early November, the company posted earnings for the third quarter of 2025, reporting earnings per share of $0.16, beating market estimates by $0.02. The revenue over the period was more than $207 million, up close to 14% compared to the revenue over the same period last year and missing analyst expectations by close to $11 million. The firm also modified 2025 revenue guidance of $800 to $850 million versus the $852 million consensus.

Corcept Therapeutics Incorporated (NASDAQ:CORT) engages in the discovery and development of medications for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

While we acknowledge the potential of CWAN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term

Disclosure: None.